Suppression of Nonsense Mutations in the Dystrophin Gene by a Suppressor tRNA Gene.

Kiselev, A. V.; Ostapenko, O. V.; Rogozhkina, E. V.; Kholod, N. S.; Seit-Nebi, A. S.; Baranov, A. N.; Lesina, E. A.; Ivashchenko, T. E.; Sabetskii, V. A.; Shavlovskii, M. M.; Rechinsky, V. O.; Kisselev, L. L.; Baranov, V. S.

Nonsense mutations in the dystrophin gene are the cause of Duchenne muscular dystrophy (DMD) in 10–15% of patients. In such an event, one approach to gene therapy for DMD is the use of suppressor tRNAs to overcome the premature termination of translation of the mutant mRNA. We have carried out cotransfection of the HeLa cell culture with constructs containing a suptRNA gene (pcDNA3suptRNA) and a marker LacZ gene (pNTLacZhis) using their polymer VSST-525 complexes. It was found that the number of cells producing β-galactosidase depends inversely on the dose of the suptRNA gene. A single in vivo injection of the construct providing for expression of the suptRNAochre gene into mdx mouse muscle resulted in the production of dystrophin in 2.5% of fibers. This suggests that suppressor tRNAs are applicable in gene therapy for hereditary diseases caused by nonsense mutations.

GENETICS; THERAPEUTICS; GENETIC mutation; MEMBRANE proteins; GENE therapy; GENETIC engineering

Molecular Biology, 2002, Vol 36, Issue 1, p30

0026-8933

Academic Journal

10.1023/A:1014238221426